Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2537095 | 0.81 | PKM (0.34) | SMN1; SMN2ADORA2BPIK3CAPDE7ARAB9A | |
| SCHEMBL18711461 | 0.81 | PIK3CA (0.34) | SMN1; SMN2ADORA2BADORA2APIK3CAPDE7A | |
| SCHEMBL21536748 | 0.81 | SMN1; SMN2 (0.39) | SMN1; SMN2ADORA2BADORA2AALDH1A1TP53 | |
| SCHEMBL5579371 | 0.81 | ALDH1A1 (0.41) | SMN1; SMN2ADORA2BADORA2AHTTALDH1A1 | |
| SCHEMBL14850021 | 0.78 | PIK3CA (0.33) | SMN1; SMN2PIK3CAPDE7A | |
| SCHEMBL23500391 | 0.78 | GAA (0.33) | SMN1; SMN2HTTGAAL3MBTL1 | |
| SCHEMBL19492381 | 0.75 | ADORA2B (0.35) | ADORA2BADORA2APIK3CAPDE7A | |
| SCHEMBL18701516 | 0.75 | ADORA2A (0.32) | ADORA2APIK3CA | |
| SCHEMBL18711470 | 0.75 | ADORA2B (0.33) | ADORA2BADORA2APIK3CA | |
| SCHEMBL23513918 | 0.74 | KCNH2 (0.34) | SMN1; SMN2ADORA2BADORA2APDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3404031-B1 | THIENO[3,2-D]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-09-23 | — | — | EP | disclosed |
| US-20170298079-A1 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298079-A1 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-19 | — | — | US | disclosed |
| US-9556199-B2 | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-31 | — | — | US | disclosed |
| US-9556199-B2 | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-31 | — | — | US | disclosed |
| US-20160168164-A1 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | US | disclosed |
| US-20160168164-A1 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | US | disclosed |
| WO-2015014815-A1 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN R&D IRELAND (IE) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168164-A1 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMS, TYMP, UMPS | SMN1; SMN2 1618/4885ADORA2B 156/4885ADORA2A 139/4885 |
| US-20170298079-A1 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMS, TYMP, UMPS | SMN1; SMN2 1618/4885ADORA2B 156/4885ADORA2A 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.